#bispecificantibody
LightNews LightNews
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press) 🎇📷 Novel Modality | Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design academic.oup.com/abt/article/... #SingleDomainAntibody #LightChainOnly #BispecificAntibody
January 27, 2026 at 1:11 AM
dengyuemedicine.bsky.social
Zanidatamab (Baihe’an®): Un avance clave en el cáncer de vías biliares HER2 positivo

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Zanidatamab #BaiheAn #HER2 #BiliaryTractCancer #Oncology #BispecificAntibody #TargetedTherapy #BreakthroughTherapy #CSCO #CDE #FDA
January 21, 2026 at 8:42 AM
pharmaphorum.bsky.social
#JohnsonandJohnson has claimed FDA approval for #RybrevantFaspro, a subcutaneous version of its EGFRxMET #bispecificantibody, for all the indications approved for the current, intravenous formulation. #NSCLC

pharmaphorum.com/news/jjs-sub...
J&J's subcutaneous Rybrevant cleared by FDA
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
pharmaphorum.com
December 19, 2025 at 9:58 AM
cancergrace.bsky.social
Now live!

Our first panel discussion from Lung Cancer OncTalk 2025 is here. Drs. @lungoncdoc, @jryckman3, and @FawziAbuRous dive deeper into #Radiotherapy and #BispecificAntibody therapies.
December 13, 2025 at 5:04 PM
dengyuemedicine.bsky.social
China NMPA Conditionally Approves Iparomlimab and Tuvonralimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #Iparomlimab #Tuvonralimab #Qibeian #CervicalCancer #Immunotherapy #BispecificAntibody #QiluPharmaceutical #ChineseInnovativeDrugs #Oncology
November 4, 2025 at 9:19 AM
sigtrans-sttt.bsky.social
Phase Ib & phase II #ClinicalTrials evaluating the safety & efficacy of KN026 with KN046, a #BispecificAntibody combination, reveals their promising efficacy and safety in HER2-positive non-breast cancers. #medsky

#STTT #OpenAccess, click here: doi.org/10.1038/s413...
September 16, 2025 at 10:30 PM
onco404.bsky.social
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #CancerAwareness #BispecificAntibody #Immunotherapy #Blinatumomab #Blincyto #Amivantamab #Rybrevant #Vocabulary
May 18, 2025 at 9:54 AM
pharmaphorum.bsky.social
NEWS: #Sanofi says it has reached an agreement with #DrenBio that would see it take control of autoimmune disease treatment DR-0201, a #bispecificantibody based myeloid cell engager with the potential to "reset the immune system."

pharmaphorum.com/news/sanofi-...
Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug
Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.
pharmaphorum.com
March 20, 2025 at 2:51 PM
tonnyjohnson.bsky.social
Bispecific Antibody Therapy: A New Hope for Treatment-Resistant Follicular Lymphoma
www.marinbio.com/bispecific-a...

#bispecificantibody #lymphoma #immunotherapy #cancer
Novel Bispecific Antibody Treatment for Drug-Resistant Lymphoma
Explore groundbreaking bispecific antibody therapy offering hope for drug-resistant follicular lymphoma patients.
www.marinbio.com
February 16, 2025 at 1:52 PM
oncodaily.bsky.social
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

oncodaily.com/science/bisp...

#AdvancedBreastCancer #ColorectalCancer #M701 #GastricCancer #LungCancer #OvarianCancer #Antibody #ASCO24 #BispecificAntibody #Catumaxomab #EpCAM #ESMO #Immunotherapy#TargetedOncology
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites - OncoDaily
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites / Advanced Breast Cancer, advanced cancer, advanced colorectal cancer, Advanced
oncodaily.com
December 12, 2024 at 3:41 PM